Fmr LLC Increases Stake in Illumina, Inc. (NASDAQ:ILMN)

Fmr LLC lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 127.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 767,294 shares of the life sciences company’s stock after purchasing an additional 429,723 shares during the quarter. Fmr LLC owned 0.48% of Illumina worth $100,063,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ILMN. Cetera Investment Advisers grew its stake in Illumina by 361.1% in the 1st quarter. Cetera Investment Advisers now owns 14,617 shares of the life sciences company’s stock worth $2,007,000 after buying an additional 11,447 shares in the last quarter. Cetera Advisors LLC purchased a new position in shares of Illumina in the first quarter worth $610,000. Mather Group LLC. raised its stake in shares of Illumina by 1,319.6% during the second quarter. Mather Group LLC. now owns 1,377 shares of the life sciences company’s stock valued at $144,000 after acquiring an additional 1,280 shares during the last quarter. Park Avenue Securities LLC raised its holdings in shares of Illumina by 61.3% during the second quarter. Park Avenue Securities LLC now owns 9,186 shares of the life sciences company’s stock valued at $959,000 after acquiring an additional 3,492 shares in the last quarter. Finally, A. D. Beadell Investment Counsel Inc. purchased a new stake in shares of Illumina in the 2nd quarter worth about $279,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Up 1.4 %

Shares of ILMN stock opened at $142.50 on Thursday. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66. The company has a market cap of $22.60 billion, a PE ratio of -14.31 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock’s 50 day simple moving average is $142.74 and its two-hundred day simple moving average is $126.57.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the business posted $0.33 EPS. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. Research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on ILMN. Stephens lifted their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Morgan Stanley reaffirmed an “equal weight” rating and set a $156.00 price objective on shares of Illumina in a research report on Tuesday, November 12th. Robert W. Baird lifted their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Leerink Partners raised their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Scotiabank reduced their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Illumina has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.